MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...

A Texas A&M lab built in the 1960s to study the universe has evolved into a world-leading facility testing electronics for ...

Good morning, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix. And we're very pleased to welcome you today to our investor call and webcast to ...

We systematically searched PubMed, Scopus, Embase, and Cochrane databases for randomized clinical trials that compared definitive radiotherapy with or without ADT in localized prostate cancer. The ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Development and validation of computational histology artificial intelligence (CHAI)–powered prognostic and predictive biomarkers in metastatic hormone-sensitive prostate cancer (mHSPC) using ENZAMET ...

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

To strengthen the public healthcare system, Cama and Albless Hospital, Fort, on March 1, opened its palliative care centre ...